As a result, there has been a substantial development of molecular therapies targeting EGFR and subsequent approval of anti-EGFR mAbs, such as cetuximab and panitumumab, for the treatment of patients with metastatic colorectal cancer [2], [27]. Here, EGFR is linked to metastatic colorectal cancer.